| Autor: |
Bian, Huijie, Zheng, Jia-Sheng, Nan, Gang, Li, Rui, Chen, Changsheng, Hu, Cai-Xia, Zhang, Yang, Sun, Bin, Wang, Xi-Long, Cui, Shi-Chang, Wu, Jiao, Xu, Jing, Wei, Ding, Zhang, Xiaoyong, Liu, Haichun, Yang, Wuwei, Ding, Yong, Li, Jing, Chen, Zhi-Nan |
| Předmět: |
|
| Zdroj: |
JNCI: Journal of the National Cancer Institute; Sep2014, Vol. 106 Issue 9, p1-1, 1p, 1 Diagram, 2 Charts, 1 Graph |
| Abstrakt: |
To assess the efficacy of combining radioimmunoconjugate [131I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0–B stage. Patients received either RFA followed by [131I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[131I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)–positive subpopulation (P = .007). [131I] metuximab may yield prevention of tumor recurrence after RFA. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
